An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases

Trial Profile

An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Tabelecleucel (Primary)
  • Indications Cancer; Lymphoma; Lymphoproliferative disorders
  • Focus Therapeutic Use
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 26 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Aug 2019.
    • 26 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2019.
    • 31 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top